• LEARN MORE ABOUT KEYNOTE 695
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact
OncoSec Medical Incorporated
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact

Press Releases

Investors

Investors

  • Overview
    • Profile
    • Contacts
  • Events & Presentations
  • Analysts
  • Press Releases
    • Email Alerts
  • Financial Info
  • Stock Info
    • Quote
    • Charts
    • Historical Data
  • Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • FAQ
  • Press Releases

  • Email Alerts

OncoSec to Present TAVO™ Immune Biomarker Data Associated with Positive Clinical Response from Ongoing KEYNOTE Studies at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

Nov 05, 2019 8:30am EST

OncoSec Provides Letter to Shareholders Regarding Recently-Announced $30 Million USD Strategic Investment at a Premium to Market

Oct 21, 2019 9:00am EDT

OncoSec Announces New Peer-Reviewed Data for TAVO™ in Virus-Associated Skin Cancer Published in Clinical Cancer Research

Oct 15, 2019 8:30am EDT

OncoSec Announces $30 Million USD Strategic Investment at a Premium to Market by China Grand Pharmaceutical and Healthcare Holdings (CGP) in Connection with Exclusive License to TAVO™ in Greater China and 35 Other Asian Countries

Oct 10, 2019 8:30am EDT

OncoSec to Present at the Cantor 2019 Global Healthcare Conference

Sep 26, 2019 8:00am EDT

OncoSec to Present at the Ladenburg Thalmann 2019 Healthcare Conference

Sep 20, 2019 8:00am EDT

OncoSec to Present at the 21st Annual H.C. Wainwright Global Investment Conference

Sep 06, 2019 8:00am EDT

OncoSec Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Application with Claims Covering Cytokine-Based Intratumoral Immunotherapies

Jul 29, 2019 8:40am EDT

OncoSec Issues Letter to Shareholders

Jul 16, 2019 8:30am EDT

OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers

Jun 27, 2019 8:30am EDT
RSS
  • Prev
    • 1...
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • ...46
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    logo

    Sign Up for our mailing list to stay current on all of our exciting new research and developments.

    Get Email Alerts
    OncoSec’s investigational products have not been approved or cleared by the FDA.

    Links

    • About
    • Pipeline
    • Technology
    • Partnering
    • Patients
    • Media
    • Investors
    • Contact
    • KEYNOTE 695 CLINICAL TRIAL

    Contact

    New Jersey Headquarters
    820 Bear Tavern Road
    Suite 200
    Ewing, NJ 08628

    R&D Laboratories
    3565 General Atomics Court #100
    San Diego, CA 92121

    p | 855.662.6732
    f | 858.430.3832

    Investors@OncoSec.com


    © 2023 OncoSec Medical Incorporated. All Rights Reserved. Q12-003052-01 REV E.